CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗在中枢神经系统肿瘤中是否有作用？
英文原题：Is There a Role for Immunotherapy in Central Nervous System Cancers?
查看英文原题
Is There a Role for Immunotherapy in Central Nervous System Cancers?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
基于抗程序性细胞死亡-1疗法在新诊断及复发患者中的III期研究均为阴性结果，胶质母细胞瘤已被认为是一种免疫治疗难治性肿瘤。此外，尽管疫苗和细胞疗法的研究仍在大量进行，但这些方法的治疗获益一直不尽如人意。关于胶质母细胞瘤所利用的多层次免疫抑制机制，越来越多的科学见解正在涌现，这为迄今令人失望的结果提供了解释，并突出了可能为基于免疫的治疗带来更大治疗获益可能性的潜在治疗途径。
展开英文摘要原文
Glioblastoma has emerged as an immunotherapy-refractory tumor based on negative phase III studies of anti-programmed cell death-1 therapy among newly diagnosed as well as recurrent patients.
In addition, although much work on vaccine and cellular approaches is ongoing, therapeutic benefit with these approaches has been underwhelming. Much scientific insight into the multitiered layers of immunosuppression exploited by glioblastoma tumors is emerging that sheds light on the explanation for the disappointing results to date and highlights possible therapeutic avenues that may offer a better likelihood of therapeutic benefit for immune-based therapies.
论文信息
- 作者
- Flores C、Dunn G、Fecci P、Lim M、Mitchell D、Reardon DA
- 第一作者单位
- Department of Neurosurgery, Preston A. Wells, JR Center for Brain Tumor Therapy at University of Florida Health, 1505 Southwest Archer Road, Gainesville, FL 32608, USA.United States
- 通讯作者单位
- Harvard Medical School, Boston, MA, USA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: david_reardon@dfci.harvard.edu.United States
- 文献类型
- 综述
- 期刊
- Hematology/oncology clinics of North America2022 Feb
- 原文标识
- PubMed 34801163 · DOI 10.1016/j.hoc.2021.09.002